Management of Delirium Tremens

Pharmacological Treatment

The American Geriatrics Society recommends benzodiazepines as the only proven first-line treatment for delirium tremens, with intravenous diazepam being the preferred agent due to its rapid onset of action, superior seizure protection, and proven mortality reduction 1, 2
Administer intravenous diazepam 10 mg initially, followed by 5-10 mg every 3-4 hours as needed for severe alcohol withdrawal with altered consciousness and delirium tremens, as suggested by the American College of Cardiology is not applicable here, however, the guideline is in line with the American Geriatrics Society 2
Benzodiazepines are the only medications proven to prevent seizures and reduce mortality from delirium tremens, according to the American Geriatrics Society 2
Long-acting benzodiazepines like diazepam provide superior protection against seizures and delirium tremens compared to shorter-acting agents through self-tapering pharmacokinetics, as stated by the guideline society 2, 3

Administer thiamine 100-500 mg IV immediately BEFORE any glucose-containing fluids to prevent or treat Wernicke encephalopathy, as recommended by the guideline society 2, 3, 4
Continue thiamine 100-300 mg/day for 2-3 months following resolution of withdrawal symptoms, according to the guideline society 2, 3

Switch to lorazepam 6-12 mg/day (short to intermediate-acting benzodiazepine) instead of diazepam in patients with severe hepatic failure, advanced liver disease, advanced age, recent head trauma, respiratory failure, or obesity, as suggested by the guideline society 2, 3, 4

Continuous monitoring of vital signs for autonomic instability (tachycardia, hypertension, fever, sweating) is essential, according to the guideline society 2
Fluid and electrolyte replacement with careful attention to magnesium levels, which are commonly depleted in chronic alcohol use, is crucial, as stated by the guideline society 2, 3

Psychiatric consultation is mandatory after stabilization for evaluation, ongoing treatment planning, and long-term abstinence strategies, as recommended by the guideline society 2, 3, 4
Consider relapse prevention medications such as acamprosate, naltrexone, disulfiram, topiramate, or baclofen after withdrawal completion, according to the guideline society 2, 4
Avoid naltrexone in patients with alcoholic liver disease due to potential hepatotoxicity, as stated by the guideline society 4

Benzodiazepines are the only medications proven to prevent seizures and reduce mortality from delirium tremens, with long-acting benzodiazepines providing superior protection against seizures and delirium through self-tapering pharmacokinetics, according to the Journal of Hepatology 5, 6
The European Society for Medical Oncology (ESMO) guidelines state that administration of either haloperidol or risperidone has no demonstrable benefit in the symptomatic management of mild-to-moderate delirium and is not recommended 7, 8, 9
The Critical Care Medicine guidelines note that no recent prospective trials have verified the safety and efficacy of haloperidol for the treatment of delirium in adult ICU patients 10, 11
In patients with hepatic dysfunction, advanced age, or respiratory compromise, short-acting lorazepam 6-12 mg/day is recommended instead of long-acting benzodiazepines, due to its no active metabolites and shorter half-life 12

Continuous vital signs monitoring in ICU or monitored ward setting is necessary due to risk of malignant arrhythmia, respiratory arrest, sepsis, or prolonged seizures, and objective bedside delirium instruments (CIWA-Ar score) should be used for routine monitoring, with scores >8 indicating moderate withdrawal, ≥15 indicating severe withdrawal requiring pharmacological treatment 12
The American College of Critical Care Medicine recommends avoiding the use of haloperidol as monotherapy for delirium tremens, as it fails to address the underlying pathophysiology and increases seizure risk, and instead recommends the use of benzodiazepines as first-line treatment 10

Avoid naltrexone in patients with alcoholic liver disease due to potential hepatotoxicity, as recommended by the Journal of Hepatology 5
Consider relapse prevention medications such as acamprosate, baclofen, or topiramate after withdrawal completion, as recommended by the Journal of Hepatology 12

Cholinesterase inhibitors, such as rivastigmine, are strongly contraindicated in delirium tremens management as they increase mortality and prolong delirium duration, according to the Intensive Care Medicine guidelines 13
The American Association for the Study of Liver Diseases recommends careful attention to magnesium levels and monitoring for hyponatremia, as its symptoms closely mimic hepatic encephalopathy and can itself precipitate encephalopathy, as stated in Clinical and Molecular Hepatology 14

Benzodiazepines are the only medications proven to prevent seizures and reduce mortality from delirium tremens in alcohol‑withdrawal hallucinations, based on extensive clinical research. Strong evidence supports their mandatory use. 15

Olanzapine may be added only when hallucinations persist despite adequately dosed benzodiazepine therapy (i.e., controlled vital signs and appropriate sedation); it should never be used as monotherapy. Moderate evidence for this adjunct role. [16][15]17
The recommendation for olanzapine derives from the European Society for Medical Oncology (ESMO) 2018 guidelines applied to cancer‑palliative care populations, not directly from alcohol‑withdrawal studies, and carries a moderate‑quality recommendation (Level III, Grade C). [16][17]
When used as an adjunct, a typical dose range is 5–10 mg of olanzapine, administered after confirming that benzodiazepine dosing is sufficient. Moderate evidence. [16][17]
Olanzapine’s sedating properties can be advantageous in patients with hyperactive delirium and persistent hallucinations, providing additional calming effect. Low‑to‑moderate evidence. [16][17]

Haloperidol and risperidone have no demonstrable benefit and may worsen symptoms in mild‑to‑moderate delirium associated with alcohol withdrawal, raising concerns about routine antipsychotic use in this setting. Low‑level evidence. [16][15]

The mandatory role of benzodiazepines is underpinned by decades of research showing mortality reduction and seizure prevention in alcohol withdrawal.
Olanzapine’s role in delirium management is based on moderate‑quality evidence (Level III‑IV) from cancer‑palliative care populations, as reflected in the ESMO 2018 guidelines; it is not a first‑line therapy for alcohol‑withdrawal hallucinations. [16][15]17